Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

INTRODUCTION: FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the nonsteroidal, selective mineralocorticoid receptor (MR) antagonist finerenone in patients with CKD and type 2 diabetes (T2D). This analysis explores the impact of use...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossing, Peter, Filippatos, Gerasimos, Agarwal, Rajiv, Anker, Stefan D., Pitt, Bertram, Ruilope, Luis M., Chan, Juliana C.N., Kooy, Adriaan, McCafferty, Kieran, Schernthaner, Guntram, Wanner, Christoph, Joseph, Amer, Scheerer, Markus F., Scott, Charlie, Bakris, George L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720648/
https://www.ncbi.nlm.nih.gov/pubmed/35005312
http://dx.doi.org/10.1016/j.ekir.2021.10.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720648/
https://www.ncbi.nlm.nih.gov/pubmed/35005312
http://dx.doi.org/10.1016/j.ekir.2021.10.008

Ejemplares similares